Does the media refer more to AXSM or JAZZ?

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Axsome Therapeutics. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 32 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.94 beat Jazz Pharmaceuticals' score of 0.35 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 11 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TEVA or AXSM?

In the previous week, Axsome Therapeutics had 25 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 32 mentions for Axsome Therapeutics and 7 mentions for Teva Pharmaceutical Industries. Axsome Therapeutics' average media sentiment score of 0.94 beat Teva Pharmaceutical Industries' score of 0.61 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or ONC?

In the previous week, Axsome Therapeutics had 27 more articles in the media than BeOne Medicines. MarketBeat recorded 32 mentions for Axsome Therapeutics and 5 mentions for BeOne Medicines. Axsome Therapeutics' average media sentiment score of 0.94 beat BeOne Medicines' score of 0.78 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or RPRX?

In the previous week, Axsome Therapeutics had 23 more articles in the media than Royalty Pharma. MarketBeat recorded 32 mentions for Axsome Therapeutics and 9 mentions for Royalty Pharma. Axsome Therapeutics' average media sentiment score of 0.94 beat Royalty Pharma's score of 0.80 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, AXSM or ZTS?

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $776.57M 13.42 -$183.17M -$3.75 N/A Zoetis $9.53B 3.36 $2.67B $6.07 12.76

Is AXSM or ZTS more profitable?

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -24.68%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Axsome Therapeutics -24.68% -265.55% -28.10% Zoetis 27.49% 74.89% 18.59%

Does the media refer more to AXSM or ZTS?

In the previous week, Axsome Therapeutics had 18 more articles in the media than Zoetis. MarketBeat recorded 32 mentions for Axsome Therapeutics and 14 mentions for Zoetis. Zoetis' average media sentiment score of 1.08 beat Axsome Therapeutics' score of 0.94 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Axsome Therapeutics (AXSM) Competitors

$199.02 -7.25 (-3.51%)

As of 08/28/2026 04:00 PM Eastern

Compare

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

Should you buy Axsome Therapeutics stock or one of its competitors? Axsome Therapeutics's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Axsome Therapeutics currently has a consensus price target of $267.60, indicating a potential upside of 34.46%. Jazz Pharmaceuticals has a consensus price target of $285.44, indicating a potential upside of 16.73%. Given Axsome Therapeutics' higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Jazz Pharmaceuticals has a net margin of 20.45% compared to Axsome Therapeutics' net margin of -24.68%. Jazz Pharmaceuticals' return on equity of 33.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Axsome Therapeutics. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 32 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.94 beat Jazz Pharmaceuticals' score of 0.35 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	11 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	13.42	-$183.17M	-$3.75	N/A
Jazz Pharmaceuticals	$4.27B	3.72	-$356.15M	$14.50	16.86

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Axsome Therapeutics had 25 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 32 mentions for Axsome Therapeutics and 7 mentions for Teva Pharmaceutical Industries. Axsome Therapeutics' average media sentiment score of 0.94 beat Teva Pharmaceutical Industries' score of 0.61 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Axsome Therapeutics' net margin of -24.68%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

Teva Pharmaceutical Industries currently has a consensus price target of $42.22, indicating a potential upside of 15.84%. Axsome Therapeutics has a consensus price target of $267.60, indicating a potential upside of 34.46%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Teva Pharmaceutical Industries has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.46	$1.41B	$0.60	60.75
Axsome Therapeutics	$776.57M	13.42	-$183.17M	-$3.75	N/A

Summary

Axsome Therapeutics beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to BeOne Medicines?

Axsome Therapeutics (NASDAQ:AXSM) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Axsome Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 27 more articles in the media than BeOne Medicines. MarketBeat recorded 32 mentions for Axsome Therapeutics and 5 mentions for BeOne Medicines. Axsome Therapeutics' average media sentiment score of 0.94 beat BeOne Medicines' score of 0.78 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus target price of $267.60, suggesting a potential upside of 34.46%. BeOne Medicines has a consensus target price of $402.14, suggesting a potential upside of 9.66%. Given Axsome Therapeutics' higher probable upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

BeOne Medicines has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	13.42	-$183.17M	-$3.75	N/A
BeOne Medicines	$5.34B	7.54	$286.93M	$5.68	64.57

BeOne Medicines has a net margin of 10.70% compared to Axsome Therapeutics' net margin of -24.68%. BeOne Medicines' return on equity of 14.23% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
BeOne Medicines	10.70%	14.23%	7.82%

Summary

BeOne Medicines beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Royalty Pharma?

Axsome Therapeutics (NASDAQ:AXSM) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Axsome Therapeutics had 23 more articles in the media than Royalty Pharma. MarketBeat recorded 32 mentions for Axsome Therapeutics and 9 mentions for Royalty Pharma. Axsome Therapeutics' average media sentiment score of 0.94 beat Royalty Pharma's score of 0.80 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 18.8% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Royalty Pharma has a net margin of 32.14% compared to Axsome Therapeutics' net margin of -24.68%. Royalty Pharma's return on equity of 30.01% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Royalty Pharma	32.14%	30.01%	14.91%

Axsome Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Axsome Therapeutics presently has a consensus target price of $267.60, suggesting a potential upside of 34.46%. Royalty Pharma has a consensus target price of $60.86, suggesting a potential upside of 0.01%. Given Axsome Therapeutics' higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	13.42	-$183.17M	-$3.75	N/A
Royalty Pharma	$2.54B	13.80	$770.95M	$1.45	41.97

Summary

Royalty Pharma beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Zoetis?

Axsome Therapeutics (NASDAQ:AXSM) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	13.42	-$183.17M	-$3.75	N/A
Zoetis	$9.53B	3.36	$2.67B	$6.07	12.76

In the previous week, Axsome Therapeutics had 18 more articles in the media than Zoetis. MarketBeat recorded 32 mentions for Axsome Therapeutics and 14 mentions for Zoetis. Zoetis' average media sentiment score of 1.08 beat Axsome Therapeutics' score of 0.94 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -24.68%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Zoetis	27.49%	74.89%	18.59%

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics presently has a consensus price target of $267.60, indicating a potential upside of 34.46%. Zoetis has a consensus price target of $107.43, indicating a potential upside of 38.71%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Summary

Zoetis beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXSM vs. The Competition

Export

Metric	Axsome Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.42B	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-53.07	787.65	273.16	25.45
Price / Sales	13.42	792.41	592.59	73.08
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	125.17	11.97	12.98	6.14
Net Income	-$183.17M	$2.83B	$3.48B	$348.86M
7 Day Performance	-4.21%	0.39%	0.13%	-0.80%
1 Month Performance	-15.18%	5.34%	7.08%	4.13%
1 Year Performance	64.10%	6.05%	24.67%	15.17%

Axsome Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXSM Axsome Therapeutics	4.2409 of 5 stars	$199.02 -3.5%	$267.60 +34.5%	+64.1%	$10.42B	$776.57M	N/A	380	News Coverage Analyst Revision
JAZZ Jazz Pharmaceuticals	4.1514 of 5 stars	$254.47 +0.1%	$272.89 +7.2%	+91.4%	$16.51B	$4.60B	17.55	2,890	Trending News Analyst Forecast Analyst Revision
TEVA Teva Pharmaceutical Industries	3.5018 of 5 stars	$36.96 -1.0%	$42.22 +14.2%	+98.0%	$43.51B	$17.26B	61.60	33,950
ONC BeOne Medicines	3.5809 of 5 stars	$371.98 -0.7%	$402.14 +8.1%	+19.8%	$41.11B	$5.34B	65.49	12,000	Insider Trade
RPRX Royalty Pharma	3.9754 of 5 stars	$61.33 +0.0%	$60.86 -0.8%	+69.1%	$35.25B	$2.38B	42.30	80	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Summary

How does Axsome Therapeutics compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Do analysts prefer AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Does the media refer more to AXSM or JAZZ?

Which has more risk & volatility, AXSM or JAZZ?

Which has better valuation and earnings, AXSM or JAZZ?

Do insiders & institutionals believe in AXSM or JAZZ?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Does the media favor TEVA or AXSM?

Is TEVA or AXSM more profitable?

Do analysts rate TEVA or AXSM?

Do institutionals & insiders have more ownership in TEVA or AXSM?

Which has more risk and volatility, TEVA or AXSM?

Which has better earnings and valuation, TEVA or AXSM?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Do insiders and institutionals believe in AXSM or ONC?

Which has more risk and volatility, AXSM or ONC?

Does the media refer more to AXSM or ONC?

Do analysts rate AXSM or ONC?

Which has stronger valuation and earnings, AXSM or ONC?

Is AXSM or ONC more profitable?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Does the media refer more to AXSM or RPRX?

Do institutionals and insiders believe in AXSM or RPRX?

Is AXSM or RPRX more profitable?

Which has more volatility & risk, AXSM or RPRX?

Do analysts prefer AXSM or RPRX?

Which has preferable valuation & earnings, AXSM or RPRX?

Summary

How does Axsome Therapeutics compare to Zoetis?

Which has higher earnings and valuation, AXSM or ZTS?

Does the media refer more to AXSM or ZTS?

Which has more volatility & risk, AXSM or ZTS?

Is AXSM or ZTS more profitable?

Do institutionals and insiders have more ownership in AXSM or ZTS?

Do analysts rate AXSM or ZTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools